Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of products with price leadership amid rising costs in the supply chain due to geopolitical tensions and policy changes affecting raw material prices [2] - The report highlights the significant price increases in pharmaceutical raw materials, particularly vitamins and amino acids, which have seen price increases of 40.54% and 84.66% respectively since the beginning of the year [2] - The report notes the approval of China's first invasive brain-machine interface, marking a significant milestone in the medical device sector [5] - The report indicates a strong trend in China's innovative pharmaceuticals going global, with a notable increase in licensing-out transactions [6] Summary by Sections 1. Supply Chain Dynamics - The report discusses the impact of rising prices in upstream chemical products on pharmaceutical raw materials, stressing that the ability to pass on these costs is crucial for maintaining profitability [2] - It mentions that 90% of monitored products have seen price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] 2. Market Trends in Disposable Gloves - The report details the price increases in disposable nitrile gloves and PVC gloves due to rising costs of raw materials like butadiene and acrylonitrile, which have increased by 84.43% and 47.30% respectively [3] - It notes that the domestic utilization rate for nitrile gloves has improved, and export prices have been rising since late 2025 [3] 3. Regulatory Environment - The report highlights the impact of dual-use item management on the pricing of key materials, creating significant price disparities between domestic and international markets [4] - It suggests that stricter controls on resources like rare earths could enhance the competitive advantage of domestic medical products [4] 4. Innovations in Medical Devices - The report discusses the approval of the brain-machine interface by the National Medical Products Administration, which is expected to open new market opportunities [5] - It outlines the potential for significant market growth in this area, given the high number of spinal cord injury patients in China [5] 5. International Expansion of Chinese Pharmaceuticals - The report notes that there have been 39 licensing-out transactions in the innovative drug sector, with upfront payments totaling approximately $2.953 billion [6] - It emphasizes that the trend of Chinese pharmaceuticals going global continues to strengthen, with a focus on small nucleic acid drugs and dual antibodies [7] 6. Stock Recommendations - The report recommends focusing on raw material suppliers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Inco Medical and Blue Sail Medical in the disposable glove sector [8] - It also suggests monitoring companies involved in the invasive brain-machine interface and small nucleic acid drugs, indicating potential for growth in these areas [8]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 中國，北京，2026年3月13日 於本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；非執行 董事為王鑫先生；以及獨立非執行董事為徐泓女士、黃德盛先生及翁杰先生。 * 僅供識別 （股 份 代 號：1858） 董事會會議通告 北京市春立正達醫療器械股份有限公司（「本公司」）之董事會（「董事會」）謹此宣 佈將於2026年3月30日（星期一）舉行董事會會議，藉以（其中包括）批准本公司及 其附屬公司截至2025年12月31日止財政年度之全年業績公佈及考慮派付末期股息 （如有）。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 代表董事會 北京市春立正達醫療器械股份有限公司 董事長 史文玲 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ...

代表董事會 北京市春立正達醫療器械股份有限公司 董事長 史文玲 （股 份 代 號：1858） 董事會會議通告 北京市春立正達醫療器械股份有限公司（「本公司」）之董事會（「董事會」）謹此宣 佈將於2026年3月30日（星期一）舉行董事會會議，藉以（其中包括）批准本公司及 其附屬公司截至2025年12月31日止財政年度之全年業績公佈及考慮派付末期股息 （如有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 中國，北京，2026年3月13日 於本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；非執行 董事為王鑫先生；以及獨立非執行董事為徐泓女士、黃德盛先生及翁杰先生。 * 僅供識 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 | RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 | RMB | | 95,140,500 | | 2. ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 | RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 | RMB | | 95,140,500 | | 2. ...

Core Viewpoint - The company reported significant growth in both revenue and net profit for the fiscal year 2025, indicating strong operational performance and effective management strategies [1] Financial Performance - The company achieved total revenue of 1.044 billion yuan, representing a year-on-year increase of 29.52% [1] - The net profit attributable to shareholders reached 272 million yuan, marking a substantial year-on-year growth of 117.72% [1] - As of the end of the reporting period, total assets amounted to 3.659 billion yuan, reflecting a growth of 5.58% compared to the beginning of the period [1] Business Development - The company's product collection and procurement have led to a sustained release of growth potential [1] - International business operations are progressing steadily, contributing to revenue growth [1] - The company continues to optimize operational management and resource allocation, enhancing operational efficiency and profitability [1]

Financial Performance Summary - The company reported a total operating revenue of 1,043,768,680.27 yuan, representing a year-on-year increase of 29.52% [2] - The net profit attributable to the parent company reached 272,124,670.05 yuan, showing a significant year-on-year growth of 117.72% [2] - Total assets at the end of the reporting period amounted to 3,659,165,538.06 yuan, an increase of 5.58% compared to the beginning of the period [2] - The equity attributable to the parent company was 2,985,050,158.61 yuan, reflecting a growth of 5.86% from the start of the period [2] - The earnings per share attributable to the parent company increased to 7.78 yuan, up by 5.86% [2] Key Growth Drivers - The growth in operating profit, total profit, and net profit attributable to the parent company was primarily driven by the normalization of national centralized procurement for orthopedic consumables, which enhanced product sales and market share [3] - The company has been advancing its internationalization strategy, achieving continuous expansion in overseas markets, which has significantly contributed to overall performance growth [3] - Operational efficiency and profitability have improved due to refined management practices and economies of scale from increased production [3]

Group 1 - The core point of the article highlights that southbound funds have increased their holdings in Chunli Medical (01858.HK) by 168,200 shares on February 27, with a total net increase of 152,000 shares over the last five trading days [1] - Over the past 20 trading days, southbound funds have reduced their holdings in Chunli Medical for 12 days, resulting in a cumulative net reduction of 1,129,700 shares [1] - As of now, southbound funds hold 41,216,800 shares of Chunli Medical, accounting for 43.31% of the company's total issued ordinary shares [1] Group 2 - Chunli Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices in China [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - The joint prosthetics product line covers four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Group 1 - The core viewpoint of the article highlights the strong financial performance of Chunli Medical, with significant growth in revenue and net profit for the fiscal year 2025 [1] Group 2 - Chunli Medical's total revenue for 2025 reached approximately 1.04 billion yuan, representing a year-on-year increase of 29.52% [1] - The net profit attributable to the parent company was approximately 272.12 million yuan, showing a remarkable year-on-year growth of 117.72% [1] - As of the end of the reporting period, total assets amounted to approximately 3.66 billion yuan, reflecting a growth of 5.58% compared to the beginning of the period [1] - The equity attributable to the parent company was approximately 2.99 billion yuan, which is a 5.86% increase from the start of the period [1] - The growth in performance is primarily attributed to increased sales following the implementation of product centralized procurement, expansion of international business, and optimization of operational efficiency [1]

Core Viewpoint - Spring Medical (688236.SH) reported a significant increase in both revenue and net profit for the fiscal year 2025, indicating strong business performance and growth potential [1] Financial Performance - The company achieved total operating revenue of 1.044 billion yuan, representing a year-on-year growth of 29.52% [1] - The net profit attributable to the parent company was 272 million yuan, reflecting a substantial year-on-year increase of 117.72% [1] Business Development - The growth potential of the company's products has been continuously released following the implementation of centralized procurement [1] - The international business is steadily advancing, contributing to the overall revenue growth [1] - Internal and external collaboration has driven stable revenue growth [1] Operational Efficiency - The company has been optimizing its management and resource allocation, leading to improved operational efficiency and profitability [1] - These enhancements have collectively supported the achievement of strong performance growth [1]